David Sinclair and Peter Attia to Co-chair $200m Biotech SPAC

[Mito]

“Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright future for healthy longevity.”


Focusing on increasing healthy longevity

Perhaps the most interesting news here is the inclusion of David Sinclair and Peter Attia, two big names in the aging research and longevity field.

David Sinclair, Professor of Genetics at Harvard Medical School, is perhaps best known for his research on nicotinamide adenine dinucleotide (NAD+) and the NAD+ precursor molecule nicotinamide mononucleotide (NMN).

David Sinclair and his team successfully launched the NAD+ Mouse Project with us here on Lifespan.io in 2018 to find out if NMN could increase healthy longevity in mice. That experiment is still currently in progress at Harvard Medical School, and we hope to bring you some news on progress later this year.

David Sinclair has also co-founded a number of biotechnology companies, including being a board member of Life Biosciences, a company and several daughter companies that all collectively work to address the nine hallmarks of aging. He is also the author of the excellent book “Lifespan – Why we age and why we don’t have to“.

Peter Attia is a practising physician who focuses on the practical application of scientific knowledge to support healthy longevity with the tools we have easily available today. As such, much of his focus is upon lifestyle, exercise, diet, sleep, and fasting as ways to maximize health and decelerate aging as much as possible. This is a sensible strategy given that technologies to increase healthy longevity could start to arrive in the next decade or two, so it’s best to stay alive in good health until then.

He hosts the Peter Attia Drive Podcast, a weekly podcast that focuses on maximizing longevity while taking into account the physical, cognitive, and emotional aspects of health. Peter Attia is also the Chief Medical Officer of the fasting app Zero, an app designed to make fasting for longevity and health purposes both safer and easier.

$200m Biotech SPAC includes David Sinclair | Lifespan.io

Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright […]

www.lifespan.io

 

[NathanK]

Probably the last two people in the world I'd want spearheading a venture in longevity. They were included largely for marketing purposes, I'm sure.

Wordsmith Peter did an interview with Sinclair a year or two ago on his podcast and both have been on Joe Rogan's individually. None of which are worth listening unless you want to know where people are taking their next fad cues from.

I expect this venture to have no tangible success beyond venture dollars acquired. It's not my money so I wish them well.

 

[GreekDemiGod]

A more complete picture of the “collapse” of NuSI, and corrections to my previous post on it

www.stephanguyenet.com

The Struggles of a $40 Million Nutrition Science Crusade

The Nutrition Science Initiative promised to study obesity and diabetes the right way. Now it’s nearly broke and all but gone.

www.wired.com

NuSI (pronounced new-see) launched in September 2012 to much fanfare, including in the pages of WIRED. It quickly raised more than $40 million from big-name donors to facilitate expensive, high-risk studies intended to illuminate the root causes of obesity. Taubes and his cofounder, physician-researcher Peter Attia, contended that nutritional science was so inconsistent partly because it was so expensive to do right. With a goal of raising an additional $190 million, they wanted to fund science that would help cut the prevalence of obesity in the US by more than half—and diabetes by 75 percent—by 2025.

ADVERTISEMENT

Rehabilitating the entire field of nutrition research was always a long shot. But six years in, NuSI is nowhere near achieving its lofty ambitions. In fact, the once-flush organization is nearly broke and all but gone.

 

[NathanK]

The world of high dollar grifters.

 

[BestSinceDAYONE]

“Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright future for healthy longevity.”


Focusing on increasing healthy longevity

Perhaps the most interesting news here is the inclusion of David Sinclair and Peter Attia, two big names in the aging research and longevity field.

David Sinclair, Professor of Genetics at Harvard Medical School, is perhaps best known for his research on nicotinamide adenine dinucleotide (NAD+) and the NAD+ precursor molecule nicotinamide mononucleotide (NMN).

David Sinclair and his team successfully launched the NAD+ Mouse Project with us here on Lifespan.io in 2018 to find out if NMN could increase healthy longevity in mice. That experiment is still currently in progress at Harvard Medical School, and we hope to bring you some news on progress later this year.

David Sinclair has also co-founded a number of biotechnology companies, including being a board member of Life Biosciences, a company and several daughter companies that all collectively work to address the nine hallmarks of aging. He is also the author of the excellent book “Lifespan – Why we age and why we don’t have to“.

Peter Attia is a practising physician who focuses on the practical application of scientific knowledge to support healthy longevity with the tools we have easily available today. As such, much of his focus is upon lifestyle, exercise, diet, sleep, and fasting as ways to maximize health and decelerate aging as much as possible. This is a sensible strategy given that technologies to increase healthy longevity could start to arrive in the next decade or two, so it’s best to stay alive in good health until then.

He hosts the Peter Attia Drive Podcast, a weekly podcast that focuses on maximizing longevity while taking into account the physical, cognitive, and emotional aspects of health. Peter Attia is also the Chief Medical Officer of the fasting app Zero, an app designed to make fasting for longevity and health purposes both safer and easier.

$200m Biotech SPAC includes David Sinclair | Lifespan.io

Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright […]

www.lifespan.io

Hasn't David Sinclair collected enough $$ from GSK and big pharma for his resveratrol scam

 

[ddjd]

“Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright future for healthy longevity.”


Focusing on increasing healthy longevity

Perhaps the most interesting news here is the inclusion of David Sinclair and Peter Attia, two big names in the aging research and longevity field.

David Sinclair, Professor of Genetics at Harvard Medical School, is perhaps best known for his research on nicotinamide adenine dinucleotide (NAD+) and the NAD+ precursor molecule nicotinamide mononucleotide (NMN).

David Sinclair and his team successfully launched the NAD+ Mouse Project with us here on Lifespan.io in 2018 to find out if NMN could increase healthy longevity in mice. That experiment is still currently in progress at Harvard Medical School, and we hope to bring you some news on progress later this year.

David Sinclair has also co-founded a number of biotechnology companies, including being a board member of Life Biosciences, a company and several daughter companies that all collectively work to address the nine hallmarks of aging. He is also the author of the excellent book “Lifespan – Why we age and why we don’t have to“.

Peter Attia is a practising physician who focuses on the practical application of scientific knowledge to support healthy longevity with the tools we have easily available today. As such, much of his focus is upon lifestyle, exercise, diet, sleep, and fasting as ways to maximize health and decelerate aging as much as possible. This is a sensible strategy given that technologies to increase healthy longevity could start to arrive in the next decade or two, so it’s best to stay alive in good health until then.

He hosts the Peter Attia Drive Podcast, a weekly podcast that focuses on maximizing longevity while taking into account the physical, cognitive, and emotional aspects of health. Peter Attia is also the Chief Medical Officer of the fasting app Zero, an app designed to make fasting for longevity and health purposes both safer and easier.

$200m Biotech SPAC includes David Sinclair | Lifespan.io

Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright […]

www.lifespan.io

View: https://twitter.com/TexasLindsay_/status/1632597837237166081?s=20